The current role and limitations of surrogate endpoints in advanced prostate cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 32, Issue 1, 2014, Pages 28.e1-28.e9

  Gomella, Leonard G ^a   Oliver Sartor, A ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Metastatic castrate resistant prostate cancer; Prostate cancer endpoints

Indexed keywords

ANTINEOPLASTIC AGENT; PROSTATE SPECIFIC ANTIGEN; BIOLOGICAL MARKER; TUMOR MARKER;

ADVANCED CANCER; BONE PAIN; BONE SCINTISCANNING; CANCER IMMUNOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; COMPUTER ASSISTED TOMOGRAPHY; DRUG APPROVAL; FOOD AND DRUG ADMINISTRATION; HUMAN; METASTATIC CASTRATE RESISTANT PROSTATE CANCER; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; BLOOD; CLINICAL TRIAL (TOPIC); DISEASE COURSE; DISEASE FREE SURVIVAL; IMMUNOTHERAPY; MALE; METHODOLOGY; PROSTATIC NEOPLASMS; TIME FACTOR; TREATMENT OUTCOME; UNITED STATES;

BIOMARKERS; BIOMARKERS, TUMOR; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; HUMANS; IMMUNOTHERAPY; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RESEARCH DESIGN; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84890801143     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2012.10.001     Document Type: Review

References (51)

1. U.S. Food and Drug Administration. FDA guidance for industry: clinical trial endpoints for the approval of cancer drugs and biologics, ; May, 2007 [accessed June 6, 2011]. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071590.pdf.
2. Eisenhauer E.A., Therasse P., Bogaerts J., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247.
3. Scher H.I., Halabi S., Tannock I., et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008, 26:1148-1159.
4. U.S. Food and Drug Administration. FDA public workshop on clinical trial endpoints in prostate cancer, ; June 21-22, 2004 [accessed June 6, 2011]. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/CancerDrugs/ucm094586.htm.
5. Moul J.W., Lipo D.R. Prostate cancer in the late 1990s: hormone refractory disease options. Urol Nurs 1999, 19:125-131.
6. Saad F., Gleason D.M., Murray R., et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004, 96:879-882.
7. Fizazi K., Carducci M., Smith M., et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011, 377:813-822.
8. Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004, 351:1502-1512.
9. Saad F., Gleason D.M., Murray R., et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002, 94:1458-1568.
10. Kantoff P.W., Higano C.S., Shore N.D., et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010, 363:411-422.
11. de Bono J.S., Oudard S., Ozguroglu M., et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010, 376:1147-1154.
12. de Bono J.S., Logothetis C.J., Molina A., et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011, 364:1995-2005.
13. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011 [press release]. Vancouver, British Columbia: PRNewswire; July 14, 2008.
14. OncoGenex Pharmaceuticals completes amendment to Phase 3 Special Protocol Assessment for confirming survival benefit in patients receiving OGX-011 with first-line docetaxel for metastatic prostate cancer [press release]. Bothell, WA, and Vancouver, British Columbia: Canada NewsWire via COMTEX News Network; June 24, 2009.
15. Teva and OncoGenex announce updates to custirsen development program in advanced prostate cancer: second phase 3 trial evaluating survival benefit of custirsen planned to initiate in 2012 [press release]. Jerusalem and Bothell, WA, and Vancouver, British Columbia: Business Wire; March 8, 2012.
16. Exelixis to initiate cabozantinib '306 trial with pain endpoint in mCRPC; Company plans to initiate '307 overall survival trial in first half of 2012 [press release]. South San Francisco, CA: Business Wire; October 31, 2011.
17. Pal S.K., Sartor O. Current paradigms and evolving concepts in metastatic castration-resistant prostate cancer. Asian J Androl 2011, 13:683-689.
18. Sartor A.O. Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space. J Hematol Oncol 2011, 4:18.
19. Bubley G.J., Carducci M., Dahut W., et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999, 17:3461-3467.
20. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000, 92:205-216.
21. Scher H.I., Warren M., Heller G. The association between measures of progression and survival in castrate-metastatic prostate cancer. Clin Cancer Res 2007, 13:1488-1492.
22. Armstrong A.J., Febbo P.G. Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature. Oncologist 2009, 14:816-827.
23. Fleming T.R. Surrogate endpoints and FDA's accelerated approval process. Health Aff 2005, 24:67-78.
24. Prentice R.L. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989, 8:431-440.
25. Jost M.M. Surrogate end points: how well do they represent patient-relevant end points?. Biomarkers Med 2007, 1:437-451.
26. Ramiah V., George D.J., Armstrong A.J. Clinical endpoints for drug development in prostate cancer. Curr Opin Urol 2008, 18:303-308.
27. Sartor O. Endpoints in prostate cancer clinical trials. Urology 2002, 60(Suppl. 3A):101-108.
28. Sternberg C.N., Petrylak D.P., Sartor O., et al. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol 2009, 27:5431-5438.
29. U.S. Food and Drug Administration. FDA briefing document: Oncology Drugs Advisory Committee Meeting; NDA 21801 Orplatna® (satraplatin capsules). July 24, 2007.
30. Scher H.I., Morris M.J., Kelly W.K., Schwartz L.H., Heller G. Prostate cancer clinical trial end points: "RECIST"ing a step backwards. Clin Cancer Res 2005, 11:5223-5232.
31. Scher H.I., Morris M.J., Basch E., Heller G. End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice. J Clin Oncol 2011, 29:3695-3704.
32. Berthold D.R., Pond G.R., Roessner M., et al. Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study. Clin Cancer Res 2008, 14:2763-2767.
33. Petrylak D.P., Ankerst D.P., Jiang C.S., et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst 2006, 98:516-521.
34. Armstrong A.J., Garrett-Mayer E., Ou Yang Y.C., et al. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol 2007, 25:3965-3970.
35. Beer T.M., Bernstein G.T., Corman J.M., et al. Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer. Clin Cancer Res 2011, 17:4558-4567.
36. Small E.J., Higano C.S., Kantoff P.W., Whitmore J.B., Frohlich M.W., Petrylak D.P. Time to disease-related pain after sipuleucel-T in asymptomatic patients with metastatic castrate-resistant prostate cancer (mCRPC): results from three randomized phase III trials. J Clin Oncol 2011, 29(Suppl.). [abstr 4661].
37. Sartor O., Petrylak D., Sternberg C., et al. Use of pain at baseline and pain progression to predict overall survival (OS) in patients (pts) with docetaxel pretreated metastatic castration-refractory prostate cancer (CRPC): results from the SPARC trial. J Clin Oncol 2009, 27(Suppl.). [abstr 5148].
38. Basch E.M., Trentacosti A., Burke L.B., et al. Measurement of pain palliation in metastatic prostate cancer: the FDA perspective. J Clin Oncol 2010, 28(Suppl.). [abstr 79].
39. Doyen J., Alix-Panabières C., Hofman P., et al. Circulating tumor cells in prostate cancer: a potential surrogate marker of survival. Crit Rev Oncol Hematol 2012, 81:241-256.
40. Danila D.C., Heller G., Gignac G.A., et al. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res 2007, 13:7053-7058.
41. de Bono J.S., Scher H.I., Montgomery R.B., et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008, 14:6302-6309.
42. Scher H.I., Heller G., Molina A., et al. Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): planned final analysis (FA) of COU-AA-301, a randomized double-blind, placebo-controlled phase III study of abiraterone acetate (AA) plus low-dose prednisone (P) post docetaxel. J Clin Oncol 2011, 29(Suppl.). [abstr LBA4517].
43. Garcia J.A., Dreicer R. Immunotherapy in castration-resistant prostate cancer: integrating sipuleucel-T into our current treatment paradigm. Oncol 2011, 25:242-249.
44. Kantoff P.W., Glode L.M., Tannenbaum S.I., Bilhartz D.L., Pittman W.G., Schuetz T.J. Randomized, double-blind, vector-controlled study of targeted immunotherapy in patients (pts) with hormone-refractory prostate cancer (HRPC). J Clin Oncol 2006, 24(Suppl.). [abstr 2501].
45. Burch P.A., Croghan G.A., Gastineau D.A., et al. Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a phase 2 trial. Prostate 2004, 60:197-204.
46. Small E.J., Schellhammer P.F., Higano C.S., et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006, 24:3089-3094.
47. Kantoff P.W., Schuetz T.J., Blumenstein B.A., et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010, 28:1099-1105.
48. Hodi F.S., O'Day S.J., McDermott D.F., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-723.
49. Scher H.I., Fizazi K., Saad F., et al. Increased Ssrvival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012, 367(13):1187-1197.
50. Parker C, Nilsson S, Heinrich D, etal. Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA). J Clin Oncol 2012;30(Suppl.): [abstr LBA4512].
51. Ryan C.J., Smith M.R., De Bono J.S., et al. Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate (AA) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2012, 30(Suppl.). [abstr LBA4518].